** Drugmaker Biohaven's BHVN.N shares jump 8.4% to $21.51 premarket
** BHVN announces up to $600 million investment from investment firm Oberland Capital in exchange for capped milestone and royalty payments on future global net sales of its experimental drug, troriluzole
** Troriluzole is currently in late-stage development for obsessive-compulsive disorder (OCD), pending approval from the U.S. Food and Drug Administration
** Oberland may purchase up to $600 million of BHVN's bonds, of which $250 million will be funded before April end
** Covington & Burling served as legal adviser to Biohaven while Cooley advised Oberland
** All 16 brokerages covering the stock rate "buy" or higher; median PT $60 - data compiled by LSEG
** As of last close, BHVN stock down 47% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。